Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study

Uncu, Dogan; Bayoglu, Ibrahim Vedat; Arslan, Ulku Yalcintas; Kucukoner, Mehmet; Artac, Mehmet; Koca, Dogan; Oguz, Arzu; Demirci, Umut; Arpaci, Erkan; Dogan, Mutlu; Kucukzeybek, Yuksel; Turker, Ibrahim; Isikdogan, Abdurrahman; Guler, Tunc; Zengin, Nurullah

추천

검색

자료유형: 학술저널

저자정보: Uncu, Dogan (Department of Medical Oncology, Education and Research Hospitals) Bayoglu, Ibrahim Vedat (Department of Medical Oncology, Education and Research Hospitals) Arslan, Ulku Yalcintas (Department of Medical Oncology, Education and Research Hospitals) Kucukoner, Mehmet (Dicle University Faculty of Medicine) Artac, Mehmet (Necmettin Erbakan University Faculty of Medicine) Koca, Dogan (Department of Medical Oncology, Education and Research Hospitals) Oguz, Arzu (Department of Medical Oncology, Education and Research Hospitals) Demirci, Umut (Department of Medical Oncology, Education and Research Hospitals) Arpaci, Erkan (Department of Medical Oncology, Education and Research Hospitals) Dogan, Mutlu (Department of Medical Oncology, Education and Research Hospitals) Kucukzeybek, Yuksel (Department of Medical Oncology, Education and Research Hospitals) Turker, Ibrahim (Department of Medical Oncology, Education and Research Hospitals) Isikdogan, Abdurrahman (Dicle University Faculty of Medicine) Guler, Tunc (Necmettin Erbakan University Faculty of Medicine) Zengin, Nurullah (Department of Medical Oncology, Education and Research Hospitals)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제9호

발행연도: 2015.1

수록면: 4,127 - 4,131 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: For HER2 positive metastatic breast cancer (MBC), continuing anti-HER2 therapy beyond progression is associated with improved outcome. However retreatment with trastuzumab after lapatinib progression is controversial. We retrospectively analyzed the efficacy of trastuzumab-based chemotherapy in HER2+ metastatic breast cancer patients whose disease progressed after lapatinib. Materials and Methods: Between October 2010 and May 2013, 54 patients whose disease progressed after lapatinib were retreated with trastuzumab-based chemotherapy. Efficacy and toxicity results were evaluated retrospectively. Results: The median age of patients was 46 (range 27-67). Fourteen patients (26%) had metastases at the time of diagnosis. All of the patients had received trastuzumab in an adjuvant or metastatic setting, while 16 (30%) had received two lines of trastuzumab. All patients had received lapatinib plus capecitabine. The median chemotherapy line for the metastatic setting was 2 (range 1-7). Cranial metastases were identified in 27 (50%) patients. 53 patients received trastuzumab-based chemotherapy following lapatinib progression while one patient received trastuzumab monotherapy. Combination chemotherapy consisted of navelbin (n=33), taxane (n=10), gemcitabine (n=2), platinum (n=2) and platinum with taxane (n=6). The median treatment cycle was 5 (range 1-44). Among 49 patients assessed for response 2 (4%) showed CR, 12 (25%) PR, 11 (22%) SD and 24 (49%) disease progression. Asymptomatic cardiotoxicity was reported in 2 (4%) of the patients. At a median follow-up of 9 months (1-39), median progression-free survival was 5 months (95% CI 4.1-5.9) and median overall survival was 10 months (95% CI 6.9-13.0). PFS and OS were not affected by the absence/presence of cranial metastases. Conclusions: Retreatment with trastuzumab-based therapy after lapatinib progression showed efficacy in heavily treated MBC patients.

#Breast cancer #metastatic #HER2 positive #trastuzumab #lapatinib #retreatment

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!